R R

What Is the Frequency of Post-Op Infections (Endophthalmitis) in Anti-VEGF Eye Injections?

Endophthalmitis is a rare but potentially devastating internal eye infection that can occur after any intraocular procedure. In the context of anti-VEGF therapy for conditions like macular degeneration or diabetic retinopathy, the infection is typically caused by bacteria entering the vitreous cavity through the needle track. Because the vitreous is a stagnant, gel-like environment, bacteria can multiply rapidly. This leads to severe inflammation that can cause permanent damage to the delicate retinal tissue within days if it is not identified and treated with emergency antibiotics.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is the Frequency of Post-Op Infections (Endophthalmitis) in Anti-VEGF Eye Injections?

Endophthalmitis is a rare but potentially devastating internal eye infection that can occur after any intraocular procedure. In the context of anti-VEGF therapy for conditions like macular degeneration or diabetic retinopathy, the infection is typically caused by bacteria entering the vitreous cavity through the needle track. Because the vitreous is a stagnant, gel-like environment, bacteria can multiply rapidly. This leads to severe inflammation that can cause permanent damage to the delicate retinal tissue within days if it is not identified and treated with emergency antibiotics.

read more about endophthalmitis anti-VEGF injection frequency ...

Copy this HTML:

Copy HTML Copied!

Average Infection Rates and Incidence Data

Large-scale registry data from 2026 indicates that the per-injection risk of endophthalmitis is remarkably low, ranging from 0.02 percent to 0.05 percent. This translates to approximately 1 infection for every 2,000 to 5,000 injections performed. While the single-injection risk is small, many patients receive monthly or bimonthly treatments for years. The cumulative risk for a patient receiving 24 injections over two years is estimated to be approximately 0.5 percent to 1 percent. These statistics vary slightly based on the specific medication used and the setting of the procedure.

Risk Ratios: Prefilled Syringes vs. Vials

One of the most significant advancements in reducing infection rates has been the shift to pre-filled syringes (PFS). Clinical data shows that using a pre-filled syringe reduces the risk of endophthalmitis by nearly 60 percent compared to traditional glass vials. When a clinician has to manually draw the medication from a vial, there are more opportunities for "table-top" contamination. In 2026, the use of PFS for medications like aflibercept (Eylea) and ranibizumab (Lucentis) is considered the gold standard for maximizing patient safety during the injection process.

Prevention Strategies and Aseptic Technique

The primary defense against infection is a rigorous aseptic protocol. The most critical component is the application of 5 percent povidone-iodine (Betadine) to the conjunctival surface at least 30 seconds before the injection. Additionally, 2026 guidelines emphasize a "no-talking" policy or the use of surgical masks for both the clinician and the patient. This is because a significant portion of post-injection infections are caused by Streptococcus species found in human saliva. Interestingly, research has consistently shown that the use of topical antibiotics after an injection does not reduce the risk of infection and may actually lead to the development of drug-resistant bacteria.

Timelines and Recovery Data

Symptoms of endophthalmitis typically appear within 2 to 7 days after the injection, with the median onset being 5 days. Early warning signs include a sudden increase in pain, new floaters, and a significant drop in vision that is often described as "looking through a fog." In 2026, roughly 50 percent of patients who receive immediate treatment (vitreous tap and antibiotic injection) are able to return to their baseline level of vision. However, the remaining 50 percent may experience a permanent loss of visual acuity, which underscores the importance of the "24-hour rule" for reporting any new post-injection pain.

FAQs on Anti-VEGF Infection Risk

Is the risk higher for certain drugs?

Some registries have suggested that aflibercept (Eylea) might have a slightly higher reported rate of infection than ranibizumab (Lucentis), but many experts believe this is due to reporting bias or differences in how the drugs are prepared. When used in pre-filled syringes, the safety profiles of the major anti-VEGF agents are nearly identical.

Can I get an infection if my eye doesn't hurt?

While pain is a hallmark symptom of endophthalmitis, some cases especially those caused by less virulent bacteria may present with only blurred vision and redness. Any significant change in your vision or the appearance of your eye in the week following an injection should be reported to your doctor immediately.

Does the injection setting (office vs. operating room) matter?

Studies have shown that injections performed in a clean office setting are just as safe as those performed in a formal operating theater. As long as the doctor follows strict povidone-iodine and masking protocols, the office remains a highly safe and efficient environment for regular anti-VEGF therapy.

When to Contact Your Retina Specialist

The first 48 to 72 hours after an injection are the most critical. While a small red spot at the injection site (subconjunctival hemorrhage) is common and harmless, you should call your specialist immediately if you experience pain that is getting worse rather than better. In 2026, retinal clinics operate under an "open door" policy for suspected infections, as every hour of delay can affect the final visual outcome. If it is after hours, do not wait until the morning; seek care at an emergency facility that has a retina specialist on call.

References

https://www.aao.org/education/clinical-statement/intravitreal-injections-statement
https://pubmed.ncbi.nlm.nih.gov/30256247/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9582495/